Clinical characteristics of dasatinib induced nephrotic syndrome in pediatric patients
| Case | Age | Sex | Diagnostic disease |
Previous TKI | Dasatinib duration |
Urine PC ratio | Kidney biopsy | Prognosis |
|---|---|---|---|---|---|---|---|---|
| [9] | 3 | F | Ph+CML | Imatinib | 17 months | 17 g/g | Global sclerosis, segmental mesangial proliferation, focal foot processes effacement | Discontinued, prednisone, ACE inhibitor remission |
| [10] | 5 | M | Ph+ALL | Imatinib | 26 days | 15.24 g/g | Fusion of foot processes | Discontinued, remission |
| [11] | 8 | F | Ph+ALL | Imatinib | 2 months | 15.29 g/g | N/A | Continuation, intermittent proteinuria |
| [12] | 14 | M | Ph+pre B ALL | N/A | 10 months | N/A | N/A | Dose reduction, recovery |
| Index | 14 | M | Ph+CML | Imatinib | 4 months | 11.7 g/g | Focal foot process effacement | Discontinued, prednisone, remission |
TKI, tyrosin kinase inhibitor; PC, protein/creatinine; Ph+, philadelphia positive; CML, chronic myelogenous leukemia; ACE inhibitor, angiotensin converting enzyme inhibitor; ALL, acute lymphoblastic leukemia; N/A, not available; Pre B ALL, precusor B cell lymphoblastic leukemia.